Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03004365 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects
A Phase 2 study, sponsored by Armata Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03004365 is a Phase 2 study that has completed, run by Armata Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT03004365, a Phase 2 study, has completed, sponsored by Armata Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this single-blind study is to evaluate whether C16G2 Varnish administered in multiple doses can effectively kill the bacteria in the oral cavity that cause dental caries.
Interventions
- DRUG C16G2 Varnish
- DRUG Placebo Varnish
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2017-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03004365
The ClinicalTrials.gov registry entry for NCT03004365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Armata Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which C16G2 Varnish is the first listed.
NCT03004365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03004365 about?
NCT03004365 is a clinical study titled "A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects". The purpose of this single-blind study is to evaluate whether C16G2 Varnish administered in multiple doses can effectively kill the bacteria in the oral cavity that cause dental caries.
What is the current status of trial NCT03004365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-01-27. Estimated completion is 2017-03-29.
What interventions are being tested in trial NCT03004365?
The interventions under investigation include: C16G2 Varnish (DRUG), Placebo Varnish (DRUG).
Who is sponsoring clinical trial NCT03004365?
This trial is sponsored by Armata Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.